Beijing Balance Medical’s subsidiary secures first China approval for collagen implant

Beijing Balance Medical Technology announced that its controlling subsidiary, Beijing Aibairui Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for its collagen implant product (collagen fiber filler-I). This product is the first in China to be registered for injection into the dermal layer of the cheek to improve skin smoothness.

The approved product features natural cross-linked type I collagen fibrils and fibers with a stable triple-helix structure, designed to integrate with the skin's collagen framework and improve extracellular matrix metabolism. Its innovative technology includes a proprietary ultra-pure extraction process and precise telopeptide removal, ensuring high human homology and minimal immunogenicity, as confirmed by clinical trials.

This approval represents a significant achievement for the company’s animal-derived implantable materials research and innovation platform. The actual sales performance of the collagen implant after launch will be subject to market promotion effects and competitive environment changes, introducing uncertainties regarding its impact on future operating revenue.